Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis

Small-cell Lung Cancer Clinical Trial

— ROSALIND  

Official title:

Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis: A 3 Cohorts Case Control Matched Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06160596
• Other study ID #: 2022-A02541-42
• Status: Recruiting
• Start date: November 1, 2023
• Est. completion date: May 1, 2028

Study information

• Verified date: November 2023
• Source: Cure 51
• Contact: Wolikow Nicolas, Master
• Phone: 0033772042022
• Email: nicolas[@]cure51.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a retrospective, exploratory, multi-center, translational, 3 cohorts case control matched study conducted in patients harboring a solid tumor with poor prognosis who presented a long-term (case) and standard (standard) survival.

Patients with:

• Cohort A: metastatic pancreatic ductal adenocarcinoma

• Cohort B: glioblastoma IDHwt

• Cohort C: extensive small cell lung cancer

This research aims to integrate data generated from clinical records, imaging, multi-omics and bioinformatics approaches to discriminate case and control and then to identify new therapeutic targets. Analyses will be performed depending on the tumor samples available with at least 3 omics levels and according to scientific advances; genomic, epigenomic, proteomics, metabolomics, transcriptomic, microbiomic.

Description:

We propose for the first time to build a large collection of samples from unexpected survivors and controls with standard survival to identify biomarkers of resistance and/or survival which would help developing new cancer therapeutics. Biological samples and clinical records will be collected and then centralised to extract the data of any patients who have survived more than 5 years for the cohorts of PDAC and SCLC and more than 3 years for the cohort of GMB-IDHwt from the day of diagnosis. In addition to the clinical record of the patient describing his/her history (including multiscale imaging, pathology, biological sample analysis), we will collect every point of data possible with current technologies, such as multi-omics including genome, proteome, transcriptome, epigenomic, metabolome and microbiome. The data set of these multi-omic groups are combined and are complementary to identify a certain biological function and its cellular source. Such complementary effects and synergistic interactions between omic layers in the life course can only be captured by integrative study of multiple molecular layers. Artificial intelligence (AI), specifically machine learning algorithms, will also help to understand these multi-omics data. AI can also bring a new layer of biomarker discovery enabling the analysis of whole slide images of biopsies with computer vision and linking those biomarkers to the multi omics genomic features. After interpreting the comprehensive data with our set-up bioinformatics team in coordination with the various centres, we expect to find molecular signatures and consequently therapeutic approaches to address patients and physicians unmet needs.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1020
• Est. completion date: May 1, 2028
• Est. primary completion date: November 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

FOR SURVIVORS

• To be eligible the exceptional survivor patients must fulfill the following inclusion criteria:

1. Adult patient (=18 years old at diagnosis).

2. Three distinct cohorts, one of patients harbouring metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, extensive small cell lung cancer.

3. Long-term survival is defined as an exceptionally long survival = 5 years from stage IV diagnosis for PDAC, extensive SCLC, and = 3 years for GBM-IDHwt.

4. Availability of at least one block sample and associated clinical annotations with following characteristics:

• One block sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses, according to requirements specified in Lab manual

• Any treatment prior to sample acquisition must be reported - all treatments accepted (standard / targeted);

• Samples should be at least 5 years old for PDAC and SCLC and 3 years old for GBM

For CONTROL GROUPS :

• To be eligible the control patients must fulfill the following inclusion criteria:

1. =18 years old at diagnosis.

2. Three distinct cohorts, one of patients suffering from metastatic pancreatic ductal adenocarcinoma, one for glioblastoma, one for extensive small cell lung cancer.

3. Paired to long-term survivors as mentioned in the methodology section

4. Death or median overall survival with a variation of 10% before of beyond as reported in pivotal clinical trials in the specific type disease

5. Availability of at least one tumor sample and associated clinical annotations with following characteristics:

• Sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses

• Any treatment prior to sample acquisition must be reported (treatment-naive samples should be preferred) - all treatments accepted (standard / targeted).

Exclusion Criteria for both groups :

• Patient must not be enrolled if he/she fulfils one of the following non-inclusion criteria:

1. <18 years old at diagnosis.

2. Hematological malignancy or solid tumors, which are not in the scope of tumor types, described in the inclusion criteria.

3. Tumor sample not available or not reaching the required quality for multi-omic analyses.

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma, IDH-wildtype
• Pancreas Adenocarcinoma
• Small Cell Lung Carcinoma
• Small-cell Lung Cancer

Intervention

Genetic:
• Long term survival multimodal analysis
To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs. To describe global signatures in the overall population (pan-cohort). To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)

Locations

Country	Name	City	State
France	Gustave Roussy Cancer Campus, Grand Paris	Villejuif

Sponsors (6)

Lead Sponsor	Collaborator
Cure 51	Centre Leon Berard, Charite University, Berlin, Germany, Gustave Roussy, Cancer Campus, Grand Paris, Istituto Europeo di Oncologia, Vall d'Hebron Institute of Oncology

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	EXCEPTIONAL SURVIVAL	In this study, the primary endpoint is the long survivorship status (Y/N). Prior to locking the database, a data review meeting will be planned to review individual data and validate the Statistical Analysis Plan (SAP).; All the deviations from protocol definitions (if any) will be listed and defined as major or minor deviations in the SAP.	54 months

External Links

•   corporate website of sponsor